QUARTERLY REPORT JULY – SEPTEMBER 2004

QUARTERLY REPORT JULY – SEPTEMBER 2004

· Preclinical development of the KB3305 compound for treatment of type 2 diabetes has progressed with the aim to initiate clinical trials.
· Cost savings initiatives, including a staff reduction, have been implemented to free resources for drug development activities.
· New share issue successfully completed in October 2004, generating in total MSEK 119.6 before transaction costs.
· Net sales amounted to MSEK 8.8 (10.5).
· The loss for the period amounted to MSEK 24.9 (34.3).
· Cash flows from operating activities amounted to MSEK -24.8 (-38.2).
· Cash and cash equivalents and short-term investments amounted to MSEK 100.8 (234.6) at the end of the period.
· Loss per share for the period amounted to SEK 1.48 (2.03).

For further information, please contact
Björn O. Nilsson, President & CEO tel. +46 8 608 60 20,
Bertil Jungmar, Chief Financial Officer, tel. +46 8 608 60 52.
————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.waymaker.net/bitonline/2004/10/15/20041015BIT20060/wkr0001.pdf QUARTERLY REPORT JULY – SEPTEMBER 2004